OpRegen shows positive phase 1/2a study results for dry AMD

CHICAGO — OpRegen, a retinal pigment epithelium cell therapy transplant for dry age-related macular degeneration, has shown signs of improving the retina structurally and decreasing drusen density, according to press release from BioTime.
Early data from a phase 1/2a study also showed encouraging results in earlier-stage dry AMD, including evidence of continued presence of the transplanted cells and improvements in visual acuity, the release said.
Data from the study were presented at the American Academy of Ophthalmology annual meeting by one of its investigators, Eyal Banin, MD, PhD.

Full Story →